Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 33%
Sell 17%
Strong Sell 0%

Bulls say

Gossamer Bio is poised for success with their innovative product pipeline and strong partnerships as seen by their successful PROSERA data and positive outlook from key opinion leaders. Additionally, the company's cost-cutting measures and positive cash flow projections demonstrate their ability to navigate the competitive biopharmaceutical industry and meet their goal of NDA submission by September 2026. The recent dip in stock price provides an attractive entry point for potential investors looking to capitalize on the company's potential growth.

Bears say

Gossamer Bio is facing potential financial challenges due to its cash runway only extending until 2027. Additionally, there are uncertainties surrounding the regulatory path for its drug seralutinib, as well as doubts about the drug's market opportunity. With a new price target of $1 per share and a Neutral rating, there must be additional regulatory clarity for the company's outlook to improve.

GOSS has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 6 analysts, GOSS has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.